The decision last week by experts at the Food and Drug Administration to endorse a pair of medicines aimed at combating heart disease brought on the latest round of hand-wringing over prescription drug costs. The drugs, which work to reduce cholesterol, are projected to cost anywhere from $7,000 to $12,000 annually once on the market.
